Next-generation sequencing (NGS) enhances the molecular characterization of myeloproliferative neoplasms (MPNs) by revealing driver and co-mutation profiles.
2
Approximately 90% of MPNs carry mutations in three driver genes: JAK2, CALR, or MPL, which are crucial for accurate diagnostics.
3
The National Comprehensive Cancer Network (NCCN) now recommends NGS panels for diagnosing and prognosticating MPNs, especially in triple-negative cases.
4
NGS can uncover significant co-mutations that may influence prognosis and therapy, which traditional PCR testing might miss.
5
Case studies demonstrate that NGS can alter diagnoses and treatment strategies by identifying additional mutations not detected by standard PCR.
